Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma—a systematic review and meta-analysis

Bunduc, Ștefania; Gede, Noémi; Váncsa, Szilárd; Lillik, Veronika; Kiss, Szabolcs; Juhász, Márk; Erőss, Bálint; Gheorghe, Cristian; Mikó, Alexandra

doi:10.1016/j.trsl.2022.01.001

Cited by 14 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, many meta-analyses have confirmed the unique diagnostic and prognostic value of CTCs [92][93][94][95]. The same properties are attributed by meta-analyses to circulating EVs [96][97][98][99]. We conjecture that both of these laboratory markers will soon be introduced into run-of-the-mill clinical diagnostics and that the interpretation of the results may be helped by artificial intelligence and machine learning [30].…”

Section: Advantages Limitations Pros and Consmentioning

confidence: 73%

Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?

Słomka¹,

Wang²,

Mocan³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be a game changer in cancer diagnosis or cancer screening. But, during their clinical use limitations were observed from statistical significance and questions raised regarding their robustness, that eventually led to be dropped from associated clinical guidelines for certain applications including cancer diagnosis. The purpose of this review isn't to give a broad overview of all current liquid biopsy as biomarkers, weight them and promise a brighter future in cancer prevention, but rather to take a deeper look on two of those who do qualify to be called liquid biopsies now or then. These two are probably of greatest interest conceptually and methodically, and likely have the highest chances to be in clinical use soon, with a portfolio extension over their original conceptual usage. We aim to dig deeper beyond cancer diagnosis or cancer screening. Actually, we aim to review in depth extracellular vesicles (EVs) and compare with circulating tumour cells (CTCs). The latter methodology is partially FDA approved and in clinical use. We will lay out similarities as taking advantage of surface antigens on EVs and CTCs in case of characterization and quantification. But drawing readers' attention to downstream application based on capture/isolation methodology and simply on their overall nature, here apparently being living material eventually recoverable as CTCs are vs. dead material with transient effects on recipient cell as in case of EVs. All this we try to bring in perspective, compare and conclude towards which future direction we are aiming for, or should aim for. Do we announce a winner between CTCs vs EVs? No, but we provide good reasons to intensify research on them.

show abstract

Section: Advantages Limitations Pros and Consmentioning

confidence: 73%

Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?

Słomka¹,

Wang²,

Mocan³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…Therefore, at present, EVs can only serve as a valid reference in disease diagnosis, and further large-scale studies are required to establish them as a diagnostic standard. A meta-analysis incorporating the detection of positive EV biomarkers of exoDNA KRASmut, ExmiR 451 a, ExmiR 200 b, ExmiR 222, and so on in 634 patients indicated that the presence of positive EV biomarkers in the blood varied in correlation with mortality at different stages of pancreatic ductal adenocarcinoma treatment [ 173 ]. This illustrates the effectiveness of EVs in disease prognosis, as endothelium-derived EVs expressing CD146 and CD105 were significantly predictive of overall survival in metastatic colorectal cancer [ 174 ].…”

Section: Loaded Cargos Of Microneedlesmentioning

confidence: 99%

Research Progress of Extracellular Vesicles-Loaded Microneedle Technology

Wang,

Cheng,

2024

Pharmaceutics

View full text Add to dashboard Cite

Microneedles (MNs), renowned for their painless and minimally invasive qualities, exhibit significant potential for facilitating effective drug delivery, vaccination, and targeted sample extraction. Extracellular vesicles (EVs), serving as cargo for MNs, are naturally occurring nanovesicles secreted by cells and characterized by novel biomarkers, low immunogenicity, and cell-source-specific traits. MNs prove instrumental in extracting EVs from the sample fluid, thereby facilitating a promising diagnostic and prognostic tool. To harness the therapeutic potential of EVs in tissue repair, MNs with sustained delivery of EVs leverage micron-sized channels to enhance targeted site concentration, demonstrating efficacy in treating various diseases, such as Achillea tendinopathy, hair loss, spinal cord injury, and diabetic ulcers. EV-loaded MNs emerge as a promising platform for repair applications of skin, cardiac, tendon, hair, and spinal cord tissues. This review commences with an overview of MNs, subsequently delving into the role of EVs as cargo for MNs. The paper then synthesizes the latest advancements in the use of EV-loaded MNs for tissue regenerative repair, extending to research progress in extracting EVs from MNs for disease diagnosis and prognostic evaluations. It aims to offer valuable insights and forecast future research trajectories with the hope of inspiring innovative ideas among researchers in this field.

show abstract

“…The recent meta-analytic data in the study by Bunduc et al, which included 634 patients from eleven studies, demonstrated several exosomal biomarkers that were correlated with an elevated mortality risk, with their pre-operative levels being increased in resectable cases, compared to non-resectable ones [ 204 ].…”

Section: Evs As Prognostic Tools In Pdacmentioning

confidence: 99%

A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment

Trifylli,

Kriebardis,

Koustas

et al. 2024

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies worldwide, while it persists as the fourth most prevalent cause of cancer-related death in the United States of America. Although there are several novel therapeutic strategies for the approach of this intensely aggressive tumor, it remains a clinical challenge, as it is hard to identify in early stages, due to its asymptomatic course. A diagnosis is usually established when the disease is already in its late stages, while its chemoresistance constitutes an obstacle to the optimal management of this malignancy. The discovery of novel diagnostic and therapeutic tools is considered a necessity for this tumor, due to its low survival rates and treatment failures. One of the most extensively investigated potential diagnostic and therapeutic modalities is extracellular vesicles (EVs). These vesicles constitute nanosized double-lipid membraned particles that are characterized by a high heterogeneity that emerges from their distinct biogenesis route, their multi-variable sizes, and the particular cargoes that are embedded into these particles. Their pivotal role in cell-to-cell communication via their cargo and their implication in the pathophysiology of several diseases, including pancreatic cancer, opens new horizons in the management of this malignancy. Meanwhile, the interplay between pancreatic carcinogenesis and short non-coding RNA molecules (micro-RNAs or miRs) is in the spotlight of current studies, as they can have either a role as tumor suppressors or promoters. The deregulation of both of the aforementioned molecules leads to several aberrations in the function of pancreatic cells, leading to carcinogenesis. In this review, we will explore the role of extracellular vesicles and miRNAs in pancreatic cancer, as well as their potent utilization as diagnostic and therapeutic tools.

show abstract

Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma—a systematic review and meta-analysis

Cited by 14 publications

References 43 publications

Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?

Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?

Research Progress of Extracellular Vesicles-Loaded Microneedle Technology

A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment

Contact Info

Product

Resources

About